These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 34261423)

  • 1. Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting.
    Varettoni M; Mangiacavalli S; Rattotti S; Cartia CS; Cavalloni C; Rossetti F; Ferretti VV; Bergamini F; Trotti C; Fiorelli N; Pagani G; Zerbi C; Ferrari J; Cristinelli C; Muzzi A; Marena C; Baldanti F; Bruno R; Arcaini L
    Leuk Lymphoma; 2021 Dec; 62(13):3311-3312. PubMed ID: 34261423
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.
    Seval GC; Topçuoğlu P; Demirer T
    Turk J Med Sci; 2021 Dec; 51(6):2799-2809. PubMed ID: 33705648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for SARS-COV-2 Using RT-qPCR in Patients with Hematologic Neoplasms Receiving Chemotherapy.
    Santarelli IM; Sierra M; Fernández SI
    Prague Med Rep; 2023; 124(1):33-39. PubMed ID: 36763829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.
    Morales-Ortega A; García de Tena J; Frutos-Pérez B; Jaenes-Barrios B; Farfán-Sedano AI; Canales-Albendea MÁ; Bernal-Bello D
    Cancer; 2021 Jun; 127(11):1937-1938. PubMed ID: 33721325
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.
    Cattaneo C; Cairoli R; Rossi G
    Cancer; 2021 Jun; 127(11):1939. PubMed ID: 33721356
    [No Abstract]   [Full Text] [Related]  

  • 6. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.
    Niu A; Ning B; Socola F; Safah H; Reynolds T; Ibrahim M; Safa F; Alfonso T; Luk A; Mushatt DM; Hu T; Saba NS
    Leuk Res; 2021 Jul; 106():106582. PubMed ID: 33933714
    [No Abstract]   [Full Text] [Related]  

  • 7. [How the screening for SARS-CoV-2 should continue in patients with hematological neoplasms receiving chemotherapy?].
    Santarelli IM; Sierra M; Fernández SI
    Medicina (B Aires); 2022; 82(3):463-464. PubMed ID: 35639076
    [No Abstract]   [Full Text] [Related]  

  • 8. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.
    Tagliamento M; Agostinetto E; Bruzzone M; Ceppi M; Saini KS; de Azambuja E; Punie K; Westphalen CB; Morgan G; Pronzato P; Del Mastro L; Poggio F; Lambertini M
    Crit Rev Oncol Hematol; 2021 Jul; 163():103365. PubMed ID: 34052423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
    Villegas C; Poza M; Talayero P; Teller JMC; Zafra D; Garcia C; Vera E; Hidalgo M; Lopez N; Cuellar C; Zamanillo I; Íñiguez R; Paz-Artal E; Aguado JM; Martinez-Lopez J
    Ann Hematol; 2020 Dec; 99(12):2953-2956. PubMed ID: 32583087
    [No Abstract]   [Full Text] [Related]  

  • 10. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
    Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
    Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic characterization of COVID-19 patients with hematological cancer.
    Maia C; Martín-Sánchez E; Garcés JJ; De Cerio AL; Inogés S; Landecho MF; Gil-Alzugaray B; Perez C; Botta C; Zabaleta A; Alegre F; Rincón C; Blanco L; Sarvide S; Vilas-Zornoza A; Alignani D; Moreno C; Paiva A; Martinho A; Alves R; Colado E; Quirós C; Olid M; Blanco A; Argemi J; Paiva B; Yuste JR
    Haematologica; 2020 Dec; 106(5):1457-1460. PubMed ID: 33327714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in patients with hematological malignancies: A retrospective case series.
    Infante MS; González-Gascón Y Marín I; Muñoz-Novas C; Churruca J; Foncillas MÁ; Landete E; Marín K; Ryan P; Hernández-Rivas JÁ
    Int J Lab Hematol; 2020 Dec; 42(6):e256-e259. PubMed ID: 32749757
    [No Abstract]   [Full Text] [Related]  

  • 13. Hematological Malignancy Patients, COVID-19, and Favipiravir.
    Mungmunpuntipantip R; Wiwanitkit V
    Turk J Haematol; 2021 Dec; 38(4):331-332. PubMed ID: 34792305
    [No Abstract]   [Full Text] [Related]  

  • 14. Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.
    La Rosée F; La Rosée P
    Acta Haematol; 2021; 144(3):246-249. PubMed ID: 32818929
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India.
    Jain A; Nayak L; Kulkarni UP; Mehra N; Yanamandra U; Kayal S; Damodar S; John JM; Mehta P; Singh S; Munot P; Selvarajan S; Radhakrishnan V; Lad D; Kapoor R; Dubashi B; Bharath RS; Jain H; Jayachandran PK; Lakshmanan J; Mani T; Thorat J; Das S; Karunamurthy O; George B; Sengar M; Malhotra P
    Blood Cancer J; 2022 Jan; 12(1):2. PubMed ID: 34987161
    [No Abstract]   [Full Text] [Related]  

  • 16. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
    Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
    Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.
    Re D; Barrière J; Chamorey E; Delforge M; Gastaud L; Petit E; Chaminade A; Verrière B; Peyrade F
    Leuk Lymphoma; 2021 Dec; 62(13):3308-3310. PubMed ID: 34308748
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.
    Wu Y; Chen W; Li W; Zhao M; Wei Q; Zhang X; Mei H; Wang Y; Hu Y
    Leuk Lymphoma; 2020 Dec; 61(14):3440-3450. PubMed ID: 32840399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
    Blennow O; Salmanton-García J; Nowak P; Itri F; Van Doesum J; López-García A; Farina F; Jaksic O; Pinczés LI; Bilgin YM; Falces-Romero I; Jiménez M; Ormazabal-Vélez I; Weinbergerová B; Duléry R; Stojanoski Z; Lahmer T; Fernández N; Hernández-Rivas JÁ; Petzer V; De Jonge N; Glenthøj A; De Ramón C; Biernat MM; Fracchiolla N; Aujayeb A; Van Praet J; Schönlein M; Méndez GA; Cattaneo C; Guidetti A; Sciumè M; Ammatuna E; Cordoba R; García-Poutón N; Gräfe S; Cabirta A; Wolf D; Nordlander A; García-Sanz R; Delia M; Berg Venemyr C; Brones C; Di Blasi R; De Kort E; Meers S; Lamure S; Serrano L; Merelli M; Coppola N; Bergantim R; Besson C; Kohn M; Petiti J; Garcia-Vidal C; Dargenio M; Danion F; Machado M; Bailén-Almorox R; Hoenigl M; Dragonetti G; Chai LYA; Kho CS; Bonanni M; Liévin R; Marchesi F; Cornely OA; Pagano L
    Am J Hematol; 2022 Aug; 97(8):E312-E317. PubMed ID: 35702878
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.